Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease

被引：80

作者：

Vandenberghe, Rik ^{[1
,2
,3
]}

Adamczuk, Katarzyna ^{[1
,3
]}

Dupont, Patrick ^{[1
,3
]}

Van Laere, Koen ^{[4
]}

Chetelat, Gael ^{[5
,6
,7
,8
]}

机构：

[1] Univ Leuven, Dept Neurosci, Lab Cognit Neurol, Leuven, Belgium

[2] Katholieke Univ Leuven Hosp, Dept Neurol, B-3000 Louvain, Belgium

[3] Univ Leuven, Leuven Inst Neurosci & Dis, KU Leuven, Alzheimer Res Ctr, Leuven, Belgium

[4] Katholieke Univ Leuven Hosp, Dept Nucl Med, B-3000 Louvain, Belgium

[5] INSERM, U1077, Caen, France

[6] Univ Caen Basse Normandie, UMR S1077, Caen, France

[7] Ecole Prat Hautes Etud, UMR S1077, Caen, France

[8] CHU Caen, U1077, F-14000 Caen, France

来源：

NEUROIMAGE-CLINICAL | 2013年 / 2卷

关键词：

Flutemetamol; Florbetapir; Florbetaben; PIB; Clinic; Diagnostic; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; POSTERIOR CORTICAL ATROPHY; GRAY-MATTER LOSS; FLORBETAPIR F 18; IN-VIVO; NATIONAL INSTITUTE; SENILE PLAQUES; F-18-FDG PET; SYNAPSE LOSS;

D O I：

10.1016/j.nicl.2013.03.014

中图分类号：

R445 [影像诊断学];

学科分类号：

100207 ;

摘要：

Amyloid imaging is currently introduced to the market for clinical use. We will review the evidence demonstrating that the different amyloid PET ligands that are currently available are valid biomarkers for Alzheimer-related beta amyloidosis. Based on recent findings from cross-sectional and longitudinal imaging studies using different modalities, we will incorporate amyloid imaging into a multidimensional model of Alzheimer's disease. Aside from the critical role in improving clinical trial design for amyloid-lowering drugs, we will also propose a tentative algorithm for when it may be useful in a memory clinic environment. Gaps in our evidence-based knowledge of the added value of amyloid imaging in a clinical context will be identified and will need to be addressed by dedicated studies of clinical utility. (C) 2013 The Authors. Published by Elsevier Inc.

引用

页码：497 / 511

页数：15

共 160 条

[1]

AGGLETON JP, 1987, EXP BRAIN RES, V67, P556

[2] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].